Table 13 Total economic benefits of influenza immunisation in the school-age population, sensitivity analysis
Influenza-associated costs | Base case | Conservative | Optimistic |
|---|---|---|---|
Vaccination coverage | 50% | 30% | 70% |
Vaccine effectiveness | 50% | 19% | 68% |
Direct Costs | |||
Laboratory diagnosis | −13,270,647 | −3,025,707 | −25,267,311 |
Medical consultations | −14,578,525 | −3,323,904 | −27,757,511 |
Drugs | −2,589,893 | −590,496 | −4,931,157 |
Hospitalisations | −93,511,195 | −21,320,552 | − 178,045,314 |
Influenza immunisation of the school-aged population | 27,421,602 | 16,452,961 | 38,390,243 |
Total direct costs (Third-Party Payer perspective) | −96,528,657 | −11,807,698 | − 197,611,050 |
Indirect costs | |||
Productivity loss | −14,431,429 | −3,290,366 | −27,477,440 |
Premature death | −1,029,382 | −234,699 | −1,959,943 |
Total indirect costs | −15,460,811 | −3,525,065 | −29,437,384 |
Total cost of influenza | −111,989,467 | −15,332,762 | −227,048,433 |